Michelle L. E. Peake
Director/Board Member chez VIROPRO INC.
Profil
Michelle L.
E.
Peake is currently the Director at Viropro, Inc. since 2012 and the Chief Operating Officer at Alpha Biologics Ltd.
since 2009.
Previously, she was the Chief Executive Officer at Alpha Biologics Sdn.
Bhd.
in 2011.
Ms. Peake completed her undergraduate degree at Griffith University in 1993.
Postes actifs de Michelle L. E. Peake
Sociétés | Poste | Début |
---|---|---|
VIROPRO INC. | Director/Board Member | 19/10/2012 |
Alpha Biologics Ltd.
Alpha Biologics Ltd. Pharmaceuticals: MajorHealth Technology Alpha Biologics is a Contract Manufacturer of Biologics drugs for use in pre-clinical, Phase1 and 2 clinical trials, anywhere in the World. The life sciences industry is experiencing spiralling drug development costs that are making it increasingly difficult for biotech and pharma companies to survive, let alone prosper. Alpha Biologics has been established to address this issue by providing its clients with the opportunity to take their biologic drugs through the early clinical trial phases at a cost is easily justified. This avoids the abandonment of potential blockbuster drug programmes based simply on cost before it has been possible to demonstrate safety and early efficacy. It specialises in the production of mammalian cell secreted protein drugs, and it provide all of the necessary services required to develop and produce its clients' drugs in full compliance with U.S. and European cGMP guidelines. Its manufacturing base in Malaysia brings significant cost advantages to its customers due to the lower overhead costs compared with Europe or the U.S., whilst maintaining the highest standards of compliance. Its core team has extensive experience of designing, building and operating cGMP compliant facilities for biologic drugs in the U.S. and Europe. This core team has been strengthened by internationally trained and experienced staff from the World-wide biologics industry and academia. Its goal is to deliver drugs on time for clinical trials at a price that is affordable, thereby enabling its clients' to maintain strong drug development pipelines and realise maximum value from the investments in research and development. | Corporate Officer/Principal | - |
Anciens postes connus de Michelle L. E. Peake
Sociétés | Poste | Fin |
---|---|---|
Alpha Biologics Sdn. Bhd.
Alpha Biologics Sdn. Bhd. Pharmaceuticals: MajorHealth Technology Part of Viropro, Inc., Alpha Biologics Sdn. The private company is based in Penang, Malaysia. Bhd. develops pharmaceutical products. Alpha Biologics Sdn. was acquired by Viropro, Inc. from Alpha Biologics Ltd. on July 12, 2011 for $29.76 million. | Chief Executive Officer | - |
Formation de Michelle L. E. Peake
Griffith University | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
VIROPRO INC. | Health Technology |
Entreprise privées | 2 |
---|---|
Alpha Biologics Sdn. Bhd.
Alpha Biologics Sdn. Bhd. Pharmaceuticals: MajorHealth Technology Part of Viropro, Inc., Alpha Biologics Sdn. The private company is based in Penang, Malaysia. Bhd. develops pharmaceutical products. Alpha Biologics Sdn. was acquired by Viropro, Inc. from Alpha Biologics Ltd. on July 12, 2011 for $29.76 million. | Health Technology |
Alpha Biologics Ltd.
Alpha Biologics Ltd. Pharmaceuticals: MajorHealth Technology Alpha Biologics is a Contract Manufacturer of Biologics drugs for use in pre-clinical, Phase1 and 2 clinical trials, anywhere in the World. The life sciences industry is experiencing spiralling drug development costs that are making it increasingly difficult for biotech and pharma companies to survive, let alone prosper. Alpha Biologics has been established to address this issue by providing its clients with the opportunity to take their biologic drugs through the early clinical trial phases at a cost is easily justified. This avoids the abandonment of potential blockbuster drug programmes based simply on cost before it has been possible to demonstrate safety and early efficacy. It specialises in the production of mammalian cell secreted protein drugs, and it provide all of the necessary services required to develop and produce its clients' drugs in full compliance with U.S. and European cGMP guidelines. Its manufacturing base in Malaysia brings significant cost advantages to its customers due to the lower overhead costs compared with Europe or the U.S., whilst maintaining the highest standards of compliance. Its core team has extensive experience of designing, building and operating cGMP compliant facilities for biologic drugs in the U.S. and Europe. This core team has been strengthened by internationally trained and experienced staff from the World-wide biologics industry and academia. Its goal is to deliver drugs on time for clinical trials at a price that is affordable, thereby enabling its clients' to maintain strong drug development pipelines and realise maximum value from the investments in research and development. | Health Technology |